Optimizing treatment for low stage triple-negative breast cancer with high immune cells
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have stage I triple-negative breast cancer (tumor 2 cm or smaller, no cancer in lymph nodes) that has been removed by surgery
- Your tumor has a high level of immune cells (at least 50% if 40 or older, at least 75% if under 40)
- You did not receive chemotherapy or other cancer drugs before surgery
- You have no other cancer in the past 5 years (except for minor skin, cervical, or low-risk prostate cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study tests giving a combination of chemotherapy and immunotherapy before surgery for early stage triple negative breast cancer. The goal is to see if this approach can improve treatment outcomes and reduce the chance of the cancer coming back.
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
This trial studies the best ways to give chemotherapy before and after surgery for stage III triple-negative breast cancer. It aims to improve treatment outcomes by using a personalized approach and patient-reported data.
This trial is testing whether a shorter course of chemo plus an immunotherapy drug called pembrolizumab works as well as the standard longer treatment for early-stage triple-negative breast cancer. The goal is to reduce side effects while keeping the treatment effective.
Hear when a new Breast Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.